Studies Now Recruiting Participants
Please call 402-280-BONE(2663) or toll free at
1-800-368-5097
to inquire about our studies.

This project is
aimed at recruiting 13-14 year old girls for a study looking at the
role of dairy consumption on weight management. Adolescence has
been recognized as a key time in life in which young girls are at
risk of becoming overweight. This is a study proposing that
increasing the intake of dairy foods, which are easily accessible
and nutrient-rich, will actually help reduce the risk of becoming
overweight in these young girls.
Principal Investigator:
Joan M. Lappe, PhD, RN, FAAN
Amount of time on study: Each
child will be on study for 1 year. We will be recruiting for this
study over a 4 year period.
Your 13-14 year
old daughter may qualify for a one year research study looking at
the role of dairy intake on weight management. This study will
attempt to show that increasing the intake of dairy foods, to the
levels recommended by the American Academy of Pediatrics, will
decrease the risk of overweight in these adolescent girls.
·
5 visits (one visit
every 3 months)
·
Painless evaluations
·
Monetary Stipend will
be given at each completed visit
Inclusion/Exclusion criteria:
- Healthy 13
and 14 year old girls
- No History
of Milk Allergy or Lactose Intolerance
- No History
of Chronic Diseases
- No Use of
Medications including: steroids, weight reduction medications,
oral contraceptives, Accutane/high dose Vitamin A, ADHD
medications (except Straterra), seizure medications, or
antidepressants.
- No
Diagnosed eating disorders
Project manager: Margaret Begley, BA, BSN, RN
Contact Info:
MargaretBegley@creighton.edu or 402-280-4578

This is a study
on women between the ages of 50-55, who have good bone density and
those that may also have experienced some bone loss.
Principal Investigator:
Robert
R. Recker, MD, MACP, FACE.
This is a
genetic study where we are looking for women in a strict age group
who meet certain density standards. Those who meet these criteria
will be asked to donate blood and other samples to look at their
individual genetic make up.
Amount of Time
on Study: This study can be done in 3 visits to our office,
the visits can be right after each but they do all need to be on
different days due to lab restrictions.
Inclusion/Exclusion criteria:
Caucasian Women
age 50-55
Subjects can not
be on hormones of any kind (Exp: Estrogen, Premarin®, birth control
pills)
No osteoporosis
medication (Exp: Fosamax®, Boniva®, Actonel®, Forteo®, Evista®)
No cholesterol
medications (Exp: Lipitor)
No steroid
medications in the last 6 months (Exp: Prednisone, Cortisone)
No seizure
medications in the last 6 months (Exp:
Dilantin, Phenobarbital)
In relatively
good health
Project Manager: Jennifer A. Larsen,
R. T. (R) (BD) (ARRT), CDT
Contact Info:
JenniferLarsen@creighton.edu
or 402-280-4489

Diabetes is very
common and has many complications, including cardiovascular, renal
and nervous system effects. An increased skeletal fracture risk in
diabetes has only recently been recognized.
Principal Investigator:
Laura A. G. Armas, MD
Bone is
constantly repairing itself and this study is designed to use
various methods to determine if diabetes affects the repair process.
Amount of time on study: The study requires 3 visits to our
Center over a 2-3 month time period.
Inclusion/Exclusion criteria:
- Men and
women, age 19-50
- You must be
a Type 1 diabetic for at least 3 years
- Must be
taking insulin
- No history
of cancer (skin cancer is ok)
- No oral
steroid medications, seizure medications, osteoporosis
medications, metformin, Actos/Avandia or diuretics
- No unstable
angina, heart attack, or uncontrolled high blood pressure
Project
Manager: Julie Stubby, RN, BSN
Contact Info: JulieStubby@creighton.edu
or 402-280-4958

The purpose of this study is to compare the effects of
two FDA-approved medications on osteoporosis.
Principal Investigator: Robert
R. Recker, MD, MACP, FACE.
Length of study: 12-14 months.
This study will compare two osteoporosis medications to observe
how they improve bone health.
Inclusion/Exclusion criteria:
-
Female, age 55-89, postmenopausal for at least 2 years (i.e. at
least 2 years since last menstrual period).
- No
history of taking IV or injectable osteoporosis medications
- Not
currently on hormones, Evista®,
steroids or seizure medications
Project Manager: Julie Stubby,
RN, BSN
Contact Info: JulieStubby@creighton.edu
or 402-280-4958
Please call 402-280-BONE(2663) or toll free at 1-800-368-5097
to inquire about our studies.

To investigate underlying causes of
osteoporosis in postmenopausal women.
Principal Investigator:
Robert
R. Recker, MD, MACP, FACE.
Length of study: 4 to 6 months.
This is a study to learn more about bone
quality and causes of fracture.
Inclusion/Exclusion criteria:
-
Female 45-70 years of age, at least 4 years
past menopause, no osteoporosis treatment, steroids, or hormones
in the last 6 months.
-
A broken bone in the last 5 years that was
not a result of a car accident.
Project manager: Chris Von Buettner, RN, BSN
Contact Info:
ChristineVonBuettner@creighton.edu or 402-280-4611

This study is
looking at the effect smoking has on bone health.
Principal Investigator: Peng
Xiao, PhD
This study is looking at how smoking effects bone health and the
difference between smokers and non-smokers bones.
Amount of time on study: 1 visit
Inclusion/Exclusion criteria:
- Be Caucasian
- Be age 30-40 and pre-menopausal
- Not have taken hormones in the last year (including birth
control medications)
- Not have taken osteoporosis medication in the last year
- Not currently on any cholesterol medication
- Not have taken steroid medication in the last 6 months
- Not have taken seizure medications in the last 6 months
- Currently in good health
Project Manager:
Jennifer A. Larsen, R. T. (R) (BD) (ARRT), CDT
Contact Info:
JenniferLarsen@creighton.edu or 402-280-4489

This study focuses upon
premenopausal women. This study will fully evaluate women
with idiopathic osteoporosis (IOP), as well as women with healthy bone density to serve as
controls.
Principal Investigator:
Robert
R. Recker, MD, MACP, FACE.
Osteoporosis is most commonly diagnosed in postmenopausal women but
this study focuses upon premenopausal women. A group in whom
osteoporosis occurs not uncommonly but about which our knowledge is
woefully inadequate. Although many young women with osteoporosis
have an underlying cause (e.g., cystic fibrosis, anorexia nervosa,
glucocorticoid exposure), other young women with osteoporosis do not
have a definable cause or clear-cut risk factors. They can be said
to have idiopathic osteoporosis (IOP). This study will fully
evaluate women with IOP as well as women with healthy bone density
to serve as controls.
Amount of time on study: 6 to 8 months
Inclusion/Exclusion criteria:
Age 20-48
Pre-menopausal women
Looking for either women with osteoporosis diagnosed on our DXA
machine or women who have experienced low-trauma fractures after the
age 18.
-
no use of oral contraceptives,
depot progesterone, estrogen preparations, raloxifene, or
calcitonin within the last 3 months no use of bisphosphonates
within the last 12 months or total exposure to bisphosphonates
greater than 1 year
-
no use of PTH, glucocorticoids,
anticonvulsants, anticoagulants, diuretics, or methotrexate use
ever
-
no use of zolendronate within the
past 2 years
Project Manager:
Jeanette LeMaster, RN, CCRC
Contact: Info:
JeanetteLeMaster@creighton.edu or 402-280-4839

The purpose of
this study is to find out if giving an injection of a new product in
the hip bone can make the hip stronger and less likely to break
later on.
Principal Investigator:
Robert
R. Recker, MD, MACP, FACE.
Length of study:
3 years (10 visits total)
Some of the
persons on this study will receive one injection in one of their hip
bones. All women on the study will be receiving Fosamax®,
calcium and Vitamin D supplements while on study.
You may be able to participate in this study if you:
-
Are at least 65 years old and post-menopausal
-
Have either never received osteoporosis treatment or have taken
a bisphosphonate (such as Actonel®,
Fosamax®, or
Boniva®) for
the past 1-5 years
-
Have not been on any hormones or Evista®
in the past 12 months
Project Manager:
Jennifer A. Larsen, R. T. (R) (BD) (ARRT), CDT
Contact Info:
JenniferLarsen@creighton.edu or 402-280-4489
|